News

August 7, 2017
Not intended for U.S. and UK Media

Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States for patients with HCC more

July 27, 2017
Second quarter of 2017:

Bayer: Group performance matches prior year despite declines at Crop Science more

July 21, 2017
Not intended for U.S. and UK Media

Bayer’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement more

News Overview

Bayer Group

Interim Report Q2

On Thursday, July 27, 2017, Werner Baumann and Johannes Dietsch presented the second quarter results of Bayer AG.

more

Advancing Together: Bayer to Acquire Monsanto

The acquisition realizes the joint vision of integrated agricultural offering delivering superior solutions for growers and creates an innovation powerhouse for the next generation of farming.

more

Products

Select product

Themes

Select topic or theme

Organization

Select business area

Countries

Select country

Special Interest

Modern Slavery Act Statement
Calendar
Covestro
Foundations
Information for Patients
Sports

Media

Publications
Social Media
Videos
Apps

Follow Us

Share Price/Index